Atara Biotherapeutics (NASDAQ:ATRA) Given Neutral Rating at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2024 earnings at $0.06 EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings at ($0.73) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.25) EPS and FY2025 earnings at ($1.05) EPS.

Separately, StockNews.com upgraded shares of Atara Biotherapeutics from a sell rating to a hold rating in a report on Friday, April 5th.

Atara Biotherapeutics Stock Performance

ATRA stock opened at $0.62 on Wednesday. The firm has a 50 day moving average price of $0.68 and a 200-day moving average price of $0.67. Atara Biotherapeutics has a 52-week low of $0.20 and a 52-week high of $2.54. The firm has a market capitalization of $75.14 million, a price-to-earnings ratio of -0.29 and a beta of 0.70.

Atara Biotherapeutics (NASDAQ:ATRA) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.14. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. The firm had revenue of $27.36 million during the quarter, compared to analyst estimates of $27.00 million. As a group, sell-side analysts forecast that Atara Biotherapeutics will post -0.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Atara Biotherapeutics news, CEO Pascal Touchon sold 81,506 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $50,533.72. Following the completion of the sale, the chief executive officer now directly owns 1,829,146 shares in the company, valued at approximately $1,134,070.52. The sale was disclosed in a document filed with the SEC, which is available through this link. In other Atara Biotherapeutics news, CEO Pascal Touchon sold 81,506 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $50,533.72. Following the completion of the sale, the chief executive officer now directly owns 1,829,146 shares in the company, valued at approximately $1,134,070.52. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Anhco Nguyen sold 42,899 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $26,597.38. Following the sale, the executive vice president now owns 898,498 shares of the company’s stock, valued at $557,068.76. The disclosure for this sale can be found here. Insiders sold a total of 188,643 shares of company stock worth $120,518 in the last three months. Insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Redmile Group LLC grew its position in shares of Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after acquiring an additional 4,903,159 shares during the period. Delap Wealth Advisory LLC bought a new stake in shares of Atara Biotherapeutics during the 1st quarter valued at $29,000. Acadian Asset Management LLC grew its position in shares of Atara Biotherapeutics by 49.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after acquiring an additional 873,133 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after acquiring an additional 86,842 shares during the period. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.